Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.

被引：6
|
作者：
Mao, Lili
Cao, Yabing
Sheng, Xinan
Bai, Xue
Chi, Zhihong
Cui, Chuanliang
Wang, Xuan
Tang, Bixia
Lian, Bin
Yan, Xieqiao
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Caili
Qi, Zhong Hui
Si, Lu
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Renal Canc & Melanoma, Collaborat Innovat Ctr Canc Med, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China
[2] Kiang Wu Hosp, Macau, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.9528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9528
引用
收藏
页数：1
相关论文
共 50 条
  • [31] P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib
    de Gooijer, Mark C.
    Zhang, Ping
    Thota, Nishita
    Mayayo-Peralta, Isabel
    Buil, Levi C. M.
    Beijnen, Jos H.
    van Tellingen, Olaf
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1012 - 1019
  • [32] p16 and cdk4 are inversely expressed in malignant melanoma of higher Clark Levels
    OlaizolaHorn, S
    Ermitsch, M
    Sterry, W
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (04) : 122 - 122
  • [33] CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAFV600 Melanoma via a p53 Dependent Pathway
    Santiappillai, Nancy T.
    Abuhammad, Shatha
    Slater, Alison
    Kirby, Laura
    McArthur, Grant A.
    Sheppard, Karen E.
    Smith, Lorey K.
    CANCERS, 2021, 13 (03) : 1 - 19
  • [34] Immunohistochemical detection of CDK4 and p16(INK4) proteins in cutaneous malignant melanoma
    Wang, YL
    Uhara, H
    Yamazaki, Y
    Nikaido, T
    Saida, T
    BRITISH JOURNAL OF DERMATOLOGY, 1996, 134 (02) : 269 - 275
  • [35] Germline mutations in the p16(INK4a) binding domain of CDK4 in familial melanoma
    Zuo, L
    Weger, J
    Yang, QB
    Goldstein, AM
    Tucker, MA
    Walker, GJ
    Hayward, N
    Dracopoli, NC
    NATURE GENETICS, 1996, 12 (01) : 97 - 99
  • [36] A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6
    Jones, Rebecca
    Ruas, Margarida
    Gregory, Fiona
    Moulin, Stephanie
    Delia, Domenico
    Manoukian, Siranoush
    Rowe, Janice
    Brookes, Sharon
    Peters, Gordon
    CANCER RESEARCH, 2007, 67 (19) : 9134 - 9141
  • [37] An open-label phase 2a study of combination dabrafenib (D) and trametinib (T) in Asian patients (pts) with advanced BRAF V600-mutant acral lentiginous melanoma (ALM) or cutaneous melanoma (CM)
    Guo, J.
    Chang, W-C.
    Dechaphunkul, A.
    Fan, Y.
    Kim, T. M.
    Lin, C-C.
    Maneechavakajorn, J.
    Shin, S. J.
    Song, X.
    Cheng, S-T.
    Thongprasert, S.
    Wong, C. S.
    Wu, D.
    Zhang, X.
    Bettinger, S.
    Zhang, P.
    Mookerjee, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma
    Asp, J
    Inerot, S
    Block, JA
    Lindahl, A
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2001, 19 (01) : 149 - 154
  • [39] Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6
    Manso, Luis
    Cortes, Alfonso
    Cejalvo, Juan M.
    Morales, Serafin
    Saenz, Jose A. Garcia
    Colomer, Ramon
    Sanchez-Bayona, Rodrigo
    Silva, Jorge
    Guerra, Juan A.
    Malon, Diego
    Mouron, Silvana
    Caleiras, Eduardo
    Quintela-Fandino, Miguel
    CANCER RESEARCH, 2022, 82 (04)
  • [40] P16 PROTEINS FROM MELANOMA-PRONE FAMILIES ARE DEFICIENT IN BINDING TO CDK4
    REYMOND, A
    BRENT, R
    ONCOGENE, 1995, 11 (06) : 1173 - 1178
12345